RayKnowChina Research Map
Shortlist

Blood disorders

Lymphoma

淋巴瘤

A general term for a range of tumours of the lymphoid tissue.

Definition adapted from MeSH (US National Library of Medicine)

hospitals in mainland China
199

with a paper from 2016–2025 or a registered study

cities
62

where those hospitals are

open trials in China
573

ClinicalTrials.gov, 18 Nov 2026

Mainland China accounts for 21% of the world's English-language research papers on lymphoma, 2021–2025 (13% in 2016–2020), and 19% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

199 hospitals in 62 cities

Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 5 papers or 1 trial on lymphoma, or was a site in 9 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Beijing22
  2. Shanghai20
  3. Guangzhou16
  4. Hangzhou8
  5. Chongqing6
  6. Nanjing6
  7. Changsha5
  8. Shenzhen5
  9. Shijiazhuang5
  10. Changchun4

Each opens lymphoma in that city. 52 more cities are in the menu below.

  1. 145 papers led
  2. 142 papers led
  3. Ruijin Hospital

    上海交通大学医学院附属瑞金医院Shanghai

    97 papers led
  4. 85 papers led
  5. 83 papers led
  6. 83 papers led
  7. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    81 papers led
  8. 74 papers led
  9. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    67 papers led
  10. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    65 papers led
  11. 56 papers led
  12. 52 papers led
    No open trial led
  13. 48 papers led
  14. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    46 papers led
  15. 43 papers led
  16. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    37 papers led
  17. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    36 papers led
    No open trial led
  18. 36 papers led
  19. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    35 papers led
  20. 35 papers led
  21. 34 papers led
  22. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC

    中国医学科学院血液病医院(血液学研究所)Tianjin

    34 papers led
  23. 33 papers led
  24. 31 papers led
  25. 30 papers led
    No open trial led
  26. 29 papers led
  27. Henan Cancer Hospital

    河南省肿瘤医院Zhengzhou

    27 papers led
  28. 27 papers led
    No open trial led
  29. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    26 papers led
    No open trial led
  30. Harbin Medical University Cancer Hospital

    哈尔滨医科大学附属肿瘤医院Harbin

    26 papers led
    No open trial led
  31. 25 papers led
  32. 25 papers led
    No open trial led
  33. 25 papers led
    No open trial led
  34. 25 papers led
    No open trial led
  35. Beijing Tiantan Hospital

    首都医科大学附属北京天坛医院BeijingInternational Department

    24 papers led
  36. 24 papers led
  37. 23 papers led
    No open trial led
  38. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    23 papers led
  39. Chongqing University Cancer Hospital

    重庆大学附属肿瘤医院Chongqing

    22 papers led
    No open trial led
  40. Shanghai Ninth People's Hospital

    上海交通大学医学院附属第九人民医院Shanghai

    22 papers led
  41. 21 papers led
    No open trial led
  42. Tianjin First Central Hospital

    天津市第一中心医院Tianjin

    21 papers led
    No open trial led
  43. 20 papers led
    No open trial led
  44. 20 papers led
    No open trial led
  45. Second Hospital of Dalian Medical University

    大连医科大学附属第二医院Dalian

    20 papers led
    No open trial led
  46. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    19 papers led
    No open trial led
  47. Tongji Hospital

    同济大学附属同济医院Shanghai

    18 papers led
  48. Sichuan Cancer Hospital

    四川省肿瘤医院Chengdu

    17 papers led
    No open trial led
  49. Eye & ENT Hospital of Fudan University

    复旦大学附属眼耳鼻喉科医院Shanghai

    16 papers led
  50. 16 papers led
    No open trial led
  51. 16 papers led
    No open trial led
  52. 15 papers led
  53. 15 papers led
    No open trial led
  54. 15 papers led
  55. Xiangya Hospital

    中南大学湘雅医院Changsha

    15 papers led
    No open trial led
  56. 15 papers led
  57. 14 papers led
  58. 14 papers led
    No open trial led
  59. Xinqiao Hospital, Army Medical University

    陆军军医大学第二附属医院(新桥医院)Chongqing

    14 papers led
    No open trial led
  60. 14 papers led
  61. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    14 papers led
  62. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    13 papers led
  63. 13 papers led
  64. 13 papers led
    No open trial led
  65. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    13 papers led
    No open trial led
  66. 13 papers led
  67. Third Xiangya Hospital

    中南大学湘雅三医院Changsha

    12 papers led
    No open trial led
  68. 12 papers led
    No open trial led
  69. 11 papers led
    No open trial led
  70. Huai'an First People's Hospital

    淮安市第一人民医院Huai'an

    11 papers led
  71. Shanghai Children's Medical Center

    上海交通大学医学院附属上海儿童医学中心Shanghai

    11 papers led
    No open trial led
  72. Shanghai General Hospital

    上海市第一人民医院Shanghai

    11 papers led
  73. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    11 papers led
    No open trial led
  74. 11 papers led
    No open trial led
  75. 10 papers led
  76. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    10 papers led
    No open trial led
  77. 10 papers led
  78. Shanghai Tenth People's Hospital

    上海市第十人民医院Shanghai

    10 papers led
    No open trial led
  79. Zhujiang Hospital

    南方医科大学珠江医院Guangzhou

    10 papers led
  80. 9 papers led
    No open trial led
  81. Changhai Hospital

    海军军医大学第一附属医院(长海医院)Shanghai

    9 papers led
    No open trial led
  82. 9 papers led
    No open trial led
  83. 9 papers led
    No open trial led
  84. 9 papers led
    No open trial led
  85. Fujian Cancer Hospital

    福建省肿瘤医院Fuzhou

    9 papers led
    No open trial led
  86. 9 papers led
    No open trial led
  87. 9 papers led
    No open trial led
  88. 9 papers led
    No open trial led
  89. 8 papers led
    No open trial led
  90. 8 papers led
  91. First Affiliated Hospital of Zhejiang Chinese Medical University

    浙江中医药大学附属第一医院(浙江省中医院)Hangzhou

    8 papers led
    No open trial led
  92. 8 papers led
    No open trial led
  93. 8 papers led
    No open trial led
  94. 8 papers led
  95. Tangdu Hospital

    空军军医大学唐都医院Xi'an

    8 papers led
    No open trial led
  96. 7 papers led
    No open trial led
  97. 7 papers led
    No open trial led
  98. Beijing Ditan Hospital, Capital Medical University

    首都医科大学附属北京地坛医院Beijing

    7 papers led
    No open trial led
  99. 7 papers led
    No open trial led
  100. 7 papers led
  101. 7 papers led
    No open trial led
  102. 7 papers led
    No open trial led
  103. 7 papers led
    No open trial led
  104. Hangzhou First People's Hospital

    杭州市第一人民医院Hangzhou

    7 papers led
    No open trial led
  105. Hunan Cancer Hospital

    湖南省肿瘤医院Changsha

    7 papers led
    No open trial led
  106. Jiangxi Cancer Hospital

    江西省肿瘤医院Nanchang

    7 papers led
    No open trial led
  107. Quanzhou First Hospital, Fujian Medical University

    福建医科大学附属泉州第一医院Quanzhou

    7 papers led
    No open trial led
  108. 7 papers led
    No open trial led
  109. 7 papers led
    No open trial led
  110. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    7 papers led
    No open trial led
  111. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    7 papers led
    No open trial led
  112. 7 papers led
  113. Xinhua Hospital

    上海交通大学医学院附属新华医院Shanghai

    7 papers led
    No open trial led
  114. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    7 papers led
    No open trial led
  115. Yichang Central People's Hospital

    宜昌市中心人民医院Yichang

    7 papers led
    No open trial led
  116. Zhongda Hospital, Southeast University

    东南大学附属中大医院Nanjing

    7 papers led
    No open trial led
  117. 6 papers led
    No open trial led
  118. 6 papers led
    No open trial led
  119. 6 papers led
    No open trial led
  120. Beijing Youan Hospital, Capital Medical University

    首都医科大学附属北京佑安医院Beijing

    6 papers led
    No open trial led
  121. Changzheng Hospital

    海军军医大学第二附属医院(长征医院)Shanghai

    6 papers led
    No open trial led
  122. First Affiliated Hospital of Shandong First Medical University

    山东第一医科大学第一附属医院(山东省千佛山医院)Jinan

    6 papers led
    No open trial led
  123. Hebei Yanda Lu Daopei Hospital

    河北燕达陆道培医院Langfang

    6 papers led
    No open trial led
  124. Huadong Hospital, Fudan University

    复旦大学附属华东医院Shanghai

    6 papers led
    No open trial led
  125. Jiangsu Cancer Hospital

    江苏省肿瘤医院Nanjing

    6 papers led
    No open trial led
  126. Linyi People's Hospital

    临沂市人民医院Linyi

    6 papers led
    No open trial led
  127. Renmin Hospital

    十堰市人民医院Shiyan

    6 papers led
    No open trial led
  128. 6 papers led
    No open trial led
  129. 6 papers led
    No open trial led
  130. 6 papers led
    No open trial led
  131. 6 papers led
    No open trial led
  132. Xijing Hospital

    空军军医大学西京医院Xi'an

    6 papers led
    No open trial led
  133. 5 papers led
    No open trial led
  134. 5 papers led
    No open trial led
  135. 5 papers led
  136. 5 papers led
    No open trial led
  137. 5 papers led
    No open trial led
  138. Guangxi Medical University Cancer Hospital

    广西医科大学附属肿瘤医院Nanning

    5 papers led
    No open trial led
  139. Jinling Hospital

    东部战区总医院(金陵医院)Nanjing

    5 papers led
    No open trial led
  140. 5 papers led
    No open trial led
  141. Southwest Hospital, Army Medical University

    陆军军医大学第一附属医院(西南医院)Chongqing

    5 papers led
    No open trial led
  142. 5 papers led
    No open trial led
  143. 5 papers led
    No open trial led
  144. Beijing Boren Hospital

    北京高博博仁医院Beijing

    4 papers led
    No open trial led
  145. 4 papers led
    No open trial led
  146. 4 papers led
  147. 4 papers led
    No open trial led
  148. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    4 papers led
    No open trial led
  149. 4 papers led
    No open trial led
  150. 4 papers led
  151. Shanxi Bethune Hospital

    山西白求恩医院Taiyuan

    4 papers led
  152. West China Second University Hospital

    四川大学华西第二医院Chengdu

    4 papers led
    No open trial led
  153. Zhongshan Ophthalmic Center

    中山大学中山眼科中心Guangzhou

    4 papers led
  154. 3 papers led
    No open trial led
  155. 3 papers led
    No open trial led
  156. 3 papers led
    No open trial led
  157. Hubei Cancer Hospital

    湖北省肿瘤医院Wuhan

    3 papers led
    No open trial led
  158. Yunnan Cancer Hospital

    云南省肿瘤医院Kunming

    3 papers led
    No open trial led
  159. 2 papers led
  160. 2 papers led
  161. 2 papers led
    No open trial led
  162. 2 papers led
    No open trial led
  163. 2 papers led
    No open trial led
  164. 2 papers led
  165. 2 papers led
  166. 2 papers led
    No open trial led
  167. 2 papers led
    No open trial led
  168. 2 papers led
    No open trial led
  169. 2 papers led
    No open trial led
  170. 2 papers led
    No open trial led
  171. Shanxi Cancer Hospital

    山西省肿瘤医院Taiyuan

    2 papers led
  172. 2 papers led
    No open trial led
  173. 2 papers led
  174. 2 papers led
  175. 1 paper led
  176. 1 paper led
  177. 1 paper led
    No open trial led
  178. 1 paper led
  179. 1 paper led
    No open trial led
  180. 1 paper led
    No open trial led
  181. 1 paper led
    No open trial led
  182. 0 papers led
  183. 0 papers led
  184. 0 papers led
    No open trial led
  185. 0 papers led
    No open trial led
  186. Beijing Sanbo Brain Hospital

    北京三博脑科医院Beijing

    0 papers led
    No open trial led
  187. 0 papers led
  188. Fuda Cancer Hospital

    广州复大肿瘤医院Guangzhou

    0 papers led
    No open trial led
  189. 0 papers led
    No open trial led
  190. Health Hospital

    昆明霍普禾森医院Kunming

    0 papers led
    No open trial led
  191. Jilin Cancer Hospital

    吉林省肿瘤医院Changchun

    0 papers led
    No open trial led
  192. Linyi Cancer Hospital

    临沂市肿瘤医院Linyi

    0 papers led
    No open trial led
  193. Pu'er People's Hospital

    普洱市人民医院Pu'er

    0 papers led
  194. Qingdao Central Hospital

    康复大学青岛中心医院Qingdao

    0 papers led
    No open trial led
  195. 0 papers led
    No open trial led
  196. 0 papers led
    No open trial led
  197. 0 papers led
    No open trial led
  198. 0 papers led
    No open trial led
  199. 0 papers led

By university or health system 59

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    201 papers led
    5 hospitals
  2. Peking University Health Science Center

    北京大学医学部Beijing

    178 papers led
    6 hospitals
  3. Sun Yat-sen University

    中山大学Guangzhou

    176 papers led
    6 hospitals
  4. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    174 papers led
    6 hospitals
  5. Sichuan University (West China)

    四川大学华西Chengdu

    150 papers led
    4 hospitals
  6. Capital Medical University

    首都医科大学Beijing

    147 papers led
    6 hospitals
  7. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    131 papers led
    6 hospitals
  8. Zhengzhou University

    郑州大学Zhengzhou

    130 papers led
    6 hospitals
  9. Fudan University

    复旦大学Shanghai

    121 papers led
    6 hospitals
  10. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    115 papers led
    6 hospitals
  11. Nanjing Medical University

    南京医科大学Nanjing

    115 papers led
    6 hospitals
  12. Fujian Medical University

    福建医科大学Fuzhou

    82 papers led
    6 hospitals
  13. Soochow University

    苏州大学Suzhou

    77 papers led
    6 hospitals
  14. Tianjin Medical University

    天津医科大学Tianjin

    72 papers led
    6 hospitals
  15. Shandong First Medical University

    山东第一医科大学Jinan

    68 papers led
    5 hospitals
  16. Central South University (Xiangya)

    中南大学湘雅Changsha

    52 papers led
    6 hospitals
  17. Qingdao University

    青岛大学Qingdao

    46 papers led
    4 hospitals
  18. China Medical University (Shenyang)

    中国医科大学Shenyang

    44 papers led
    4 hospitals
  19. Jilin University

    吉林大学Changchun

    44 papers led
    4 hospitals
  20. Tongji University

    同济大学Shanghai

    44 papers led
    6 hospitals
  21. Shandong University

    山东大学Jinan

    42 papers led
    6 hospitals
  22. Southern Medical University

    南方医科大学Guangzhou

    41 papers led
    6 hospitals
  23. Hebei Medical University

    河北医科大学Shijiazhuang

    40 papers led
    4 hospitals
  24. Xuzhou Medical University

    徐州医科大学Xuzhou

    40 papers led
    5 hospitals
  25. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    37 papers led
    1 hospital
  26. Chongqing Medical University

    重庆医科大学Chongqing

    36 papers led
    6 hospitals
  27. Harbin Medical University

    哈尔滨医科大学Harbin

    31 papers led
    4 hospitals
  28. 31 papers led
    3 hospitals
  29. Xiamen University

    厦门大学Xiamen

    31 papers led
    2 hospitals
  30. Anhui Medical University

    安徽医科大学Hefei

    29 papers led
    5 hospitals
  31. Nanjing University

    南京大学Nanjing

    27 papers led
    4 hospitals
  32. Nanchang University

    南昌大学Nanchang

    26 papers led
    3 hospitals
  33. Nantong University

    南通大学Nantong

    25 papers led
    1 hospital
  34. Army Medical University

    陆军军医大学Chongqing

    24 papers led
    3 hospitals
  35. Chongqing University

    重庆大学Chongqing

    24 papers led
    1 hospital
  36. Guangxi Medical University

    广西医科大学Nanning

    24 papers led
    6 hospitals
  37. Wuhan University

    武汉大学Wuhan

    23 papers led
    3 hospitals
  38. Xi'an Jiaotong University

    西安交通大学Xi'an

    22 papers led
    3 hospitals
  39. Southwest Medical University

    西南医科大学Luzhou

    20 papers led
    1 hospital
  40. Wenzhou Medical University

    温州医科大学Wenzhou

    20 papers led
    6 hospitals
  41. Guangzhou Medical University

    广州医科大学Guangzhou

    18 papers led
    6 hospitals
  42. Naval Medical University

    海军军医大学Shanghai

    18 papers led
    3 hospitals
  43. 16 papers led
    1 hospital
  44. Air Force Medical University

    空军军医大学Xi'an

    15 papers led
    2 hospitals
  45. Kunming Medical University

    昆明医科大学Kunming

    13 papers led
    6 hospitals
  46. University of Chinese Academy of Sciences

    中国科学院大学Beijing

    13 papers led
    1 hospital
  47. Xinjiang Medical University

    新疆医科大学Urumqi

    13 papers led
    3 hospitals
  48. Jinan University

    暨南大学Guangzhou

    12 papers led
    1 hospital
  49. 10 papers led
    5 hospitals
  50. Jiangnan University

    江南大学Wuxi

    8 papers led
    1 hospital
  51. Shenzhen University

    深圳大学Shenzhen

    8 papers led
    5 hospitals
  52. Guizhou Medical University

    贵州医科大学Guiyang

    7 papers led
    1 hospital
  53. Shantou University Medical College

    汕头大学医学院Shantou

    6 papers led
    1 hospital
  54. Guangdong Pharmaceutical University

    广东药科大学Guangzhou

    5 papers led
    1 hospital
  55. Ningxia Medical University

    宁夏医科大学Yinchuan

    4 papers led
    1 hospital
  56. Bengbu Medical University

    蚌埠医科大学Bengbu

    3 papers led
    1 hospital
  57. Guangdong Medical University

    广东医科大学Zhanjiang

    3 papers led
    2 hospitals
  58. Chengdu University

    成都大学Chengdu

    2 papers led
    1 hospital
  59. Guilin Medical University

    桂林医学院Guilin

    2 papers led
    1 hospital

573

open trials on lymphoma in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with at least one listed hospital as lead sponsor or site. 406 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2027-02
    Posted
    Registry
    NCT06902012

    Age 18 years to Not stated (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  2. Recruiting
    GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT06875063

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  3. Recruiting
    The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
    Phase
    Not given
    Started
    2026-09
    Posted
    Registry
    NCT07039474

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First HospitalBeijing

  4. Recruiting
    Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07164560

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  5. Recruiting
    Anti CD19 Gene Therapy for B-cell Lymphoma
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07211048

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  6. Recruiting
    A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Phase
    Phase 4
    Started
    2026-03
    Posted
    Registry
    NCT07218341

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou

  7. Recruiting
    Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07300514

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  8. Recruiting
    An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
    Phase
    Early phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07344818

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's HospitalBeijing

  9. Recruiting
    U69-CART-Cells For R/R T-ALL
    Phase
    Phase 1
    Started
    2026-10
    Posted
    Registry
    NCT07350863

    Age 15 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  10. Recruiting
    T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07353840

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  11. Recruiting
    Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07372352

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  12. Recruiting
    A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07377578

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Nanning

  13. Recruiting
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07380984

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  14. Recruiting
    Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07381738

    Age 14 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai

  15. Recruiting
    A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
    Phase
    Phase 2/Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07389616

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  16. Recruiting
    CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07397832

    Age 60 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  17. Recruiting
    Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell Lymphoma
    Phase
    Phase 1
    Started
    2026-02
    Posted
    Registry
    NCT07398963

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  18. Recruiting
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07409428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou

  19. Recruiting
    PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07410520

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  20. Recruiting
    Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07414758

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai General HospitalShanghai

  21. Recruiting
    Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07416890

    Age 18 years to 80 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  22. Recruiting
    Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07418190

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  23. Recruiting
    A Study of APG-3288 in Relapsed/Refractory Blood Cancers
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07424833

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  24. Recruiting
    Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07441993

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou

  25. Recruiting
    PIC1 Injection Therapy for Relapsed/Refractory B-NHL
    Phase
    Phase 1
    Started
    2026-03
    Posted
    Registry
    NCT07456371

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  26. Recruiting
    ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07481669

    Age 18 years to 70 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  27. Recruiting
    Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07493109

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  28. Recruiting
    Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07493148

    Age 70 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  29. Recruiting
    Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07494565

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  30. Recruiting
    Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07496229

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengdu, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  31. Recruiting
    Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07499271

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  32. Recruiting
    Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07502768

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  33. Recruiting
    Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07507318

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  34. Recruiting
    The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07514169

    Age 70 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  35. Recruiting
    A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07519772

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai, Zhengzhou

  36. Recruiting
    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07523555

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  37. Recruiting
    Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07523737

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  38. Recruiting
    Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07525466

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  39. Recruiting
    CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07538635

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  40. Recruiting
    A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
    Phase
    Early phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07548697

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  41. Recruiting
    Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07554898

    Age 18 years to Not stated (registered criteria)

    Led by Zhejiang Cancer Hospital; 1 listed hospital as study siteHangzhou

  42. Recruiting
    Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07555470

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  43. Recruiting
    A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07562022

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  44. Recruiting
    A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07570017

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  45. Recruiting
    A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07570823

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  46. Recruiting
    CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07587840

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  47. Recruiting
    An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07598578

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  48. Recruiting
    JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07603479

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  49. Recruiting
    R-PMDT Regimen in Newly Diagnosed PCNSL
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07604987

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  50. Recruiting
    A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07606937

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin

  51. Recruiting
    Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07608978

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  52. Recruiting
    A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07609823

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  53. Recruiting
    A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07609862

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  54. Recruiting
    Phase I Study of FXS0683 in the Treatment of Blood Tumors
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07616089

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  55. Recruiting
    Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07620314

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  56. Recruiting
    A Phase I Study of JLM019 Injection
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07623850

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  57. Recruiting
    A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07628738

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  58. Recruiting
    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
    Phase
    Phase 2/Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07634471

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  59. Recruiting
    A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07661537

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou

  60. Recruiting
    BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
    Phase
    Phase 3
    Started
    2026-08
    Posted
    Registry
    NCT07678229

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  61. Recruiting
    Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07680933

    Age 18 years to 80 years (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  62. Recruiting
    Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07719556

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteChangzhou, Nanjing

  63. Recruiting
    Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07727083

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  64. Recruiting
    Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07749365

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  65. Recruiting
    Exploration of Circular RNA in B-cell Hematologic Malignancies
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07774572

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  66. Recruiting
    In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07775508

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  67. Recruiting
    Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07778212

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  68. Recruiting
    CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07779018

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  69. Recruiting
    CD38 Targeted -PET/ CT for Multiple Myeloma
    Phase
    N/A
    Started
    2026-07
    Posted
    Registry
    NCT07782944

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Guilin Medical UniversityGuilin

  70. Recruiting
    A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07788118

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  71. Recruiting
    A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07808827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  72. Recruiting
    A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07823829

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesShanghai, Wuhan

  73. Recruiting
    Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07839247

    Age 70 years to Not stated (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  74. Recruiting
    Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07842835

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan

  75. Recruiting
    Rapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07851363

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  76. Recruiting
    Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07864701

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  77. Recruiting
    Prospective ctDNA Testing in Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2026-10
    Posted
    Registry
    NCT07878351

    Age 18 years to Not stated (registered criteria)

    Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing

  78. Recruiting
    BEX101 in B-cell Non-Hodgkin's Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07882641

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  79. Recruiting
    Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
    Phase
    Phase 4
    Started
    2026-10
    Posted
    Registry
    NCT07908888

    Age 65 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  80. Recruiting
    GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-08
    Posted
    Registry
    NCT07910708

    Age 18 years to 75 years (registered criteria)

    Led by Pu'er People's HospitalPu'er

  81. Recruiting
    Multimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07941063

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  82. Recruiting
    An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT06487624

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Hangzhou, Yantai

  83. Recruiting
    Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06570447

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  84. Recruiting
    One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT06618313

    Age 18 years to Not stated (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  85. Recruiting
    A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06642792

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  86. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT06689917

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  87. Recruiting
    A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06697184

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Suzhou

  88. Recruiting
    A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06717347

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen

  89. Recruiting
    A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06742996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  90. Recruiting
    UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT06743503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin

  91. Recruiting
    POLA-R-CHP in the First-line Treatment of Transformed DLBCL
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06743945

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  92. Recruiting
    Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06758037

    Age 70 years to 100 years (registered criteria)

    Led by First Affiliated Hospital of Ningbo UniversityNingbo

  93. Recruiting
    Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-01
    Posted
    Registry
    NCT06758713

    Age 18 years to 75 years (registered criteria)

    Led by Third Affiliated Hospital of Southern Medical UniversityGuangzhou

  94. Recruiting
    Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06760039

    Age 18 years to 80 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen University; 5 listed hospitals as study sitesBeijing, Fuzhou, Lanzhou, Nanchang, Zhanjiang, Zhuhai

  95. Recruiting
    CHiR Therapy for Elderly DLBCL Intolerant to Chemo
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06764017

    Age 70 years to 100 years (registered criteria)

    Led by First Affiliated Hospital of Ningbo UniversityNingbo

  96. Recruiting
    A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06776952

    Age 18 days to 70 days (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  97. Recruiting
    Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06792253

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  98. Recruiting
    MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06793189

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 2 listed hospitals as study sitesBeijing, Shanghai, Shenyang

  99. Recruiting
    Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06803693

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  100. Recruiting
    A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-01
    Posted
    Registry
    NCT06820268

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shijiazhuang, Wuhan

  101. Recruiting
    A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06822868

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  102. Recruiting
    Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06826118

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  103. Recruiting
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06829771

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou

  104. Recruiting
    Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06830031

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  105. Recruiting
    Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06832267

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  106. Recruiting
    CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06834529

    Age 14 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  107. Recruiting
    Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT06838832

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  108. Recruiting
    Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06846489

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  109. Recruiting
    CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT06850285

    Age 15 years to 80 years (registered criteria)

    Led by Shanxi Bethune HospitalTaiyuan

  110. Recruiting
    Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06854445

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  111. Recruiting
    Newly-diagnosed Pediatric T-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06855810

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan

  112. Recruiting
    A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06855823

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  113. Recruiting
    Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06867536

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  114. Recruiting
    Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06874946

    Age 3 years to 70 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  115. Recruiting
    Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06883526

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  116. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT06890065

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  117. Recruiting
    Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
    Phase
    Phase 2/Phase 3
    Started
    2025-05
    Posted
    Registry
    NCT06895538

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  118. Recruiting
    Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06909474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  119. Recruiting
    A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06911502

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Jinan, Wuhan

  120. Recruiting
    A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06914037

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  121. Recruiting
    CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06925464

    Age 14 years to 70 years (registered criteria)

    Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai

  122. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2025-05
    Posted
    Registry
    NCT06940960

    Age 12 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang

  123. Recruiting
    A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06943872

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou

  124. Recruiting
    Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT06947967

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  125. Recruiting
    GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06948981

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  126. Recruiting
    Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT06958705

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  127. Recruiting
    Zanubrutinib Combined With G-CVP in Previously Untreated FL
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06959732

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  128. Recruiting
    Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT06961669

    Age 3 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  129. Recruiting
    Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06967038

    Age 18 years to 70 years (registered criteria)

    Led by Tongji HospitalShanghai

  130. Recruiting
    A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06973187

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou

  131. Recruiting
    A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
    Phase
    Early phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06976437

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Jiangsu UniversityChangzhou

  132. Recruiting
    Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06987916

    Age 2 years to 75 years (registered criteria)

    Led by Tongji HospitalShanghai

  133. Recruiting
    Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06996132

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  134. Recruiting
    A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT07000617

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing

  135. Recruiting
    Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07001540

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  136. Recruiting
    Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07002099

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  137. Recruiting
    RGL-305+ Lymphoma + Exploratory Clinical Study
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT07006012

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  138. Recruiting
    BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07009002

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  139. Recruiting
    A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07011056

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  140. Recruiting
    Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07012980

    Age 70 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  141. Recruiting
    Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT07022223

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou

  142. Recruiting
    CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07022964

    Age 14 years to 70 years (registered criteria)

    Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai

  143. Recruiting
    A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07053670

    Age 18 years to 75 years (registered criteria)

    Led by Tongji Hospital; 1 listed hospital as study siteShanghai, Wuhan

  144. Recruiting
    Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT07058103

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  145. Recruiting
    DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07059650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou

  146. Recruiting
    Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
    Phase
    Not given
    Started
    2025-05
    Posted
    Registry
    NCT07070648

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  147. Recruiting
    A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT07072169

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  148. Recruiting
    The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07073833

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai

  149. Recruiting
    Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT07074470

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  150. Recruiting
    Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07078500

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  151. Recruiting
    A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07082686

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  152. Recruiting
    Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
    Phase
    Phase 2/Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07084662

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  153. Recruiting
    Clinical Study of U01(ssCART-19) in Patients With B-Cell Lymphoma
    Phase
    Phase 1
    Started
    2025-01
    Posted
    Registry
    NCT07093073

    Age 2 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  154. Recruiting
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Early phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07093411

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad Hospital; 3 listed hospitals as study sitesBeijing, Hefei, Xi'an, Xuzhou

  155. Recruiting
    Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07093710

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  156. Recruiting
    An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
    Phase
    Early phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07101705

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  157. Recruiting
    Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07106723

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  158. Recruiting
    CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07106749

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  159. Recruiting
    uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07109518

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  160. Recruiting
    A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07124936

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou

  161. Recruiting
    Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
    Phase
    N/A
    Started
    2025-07
    Posted
    Registry
    NCT07126678

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  162. Recruiting
    GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07138547

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  163. Recruiting
    A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07139873

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin

  164. Recruiting
    SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07153068

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  165. Recruiting
    A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07154264

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou

  166. Recruiting
    Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07159620

    Age 14 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  167. Recruiting
    Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
    Phase
    Early phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07162012

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  168. Recruiting
    Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07165769

    Age 18 years to 80 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  169. Recruiting
    Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07168317

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  170. Recruiting
    Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
    Phase
    Phase 2/Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07168980

    Age Not stated to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  171. Recruiting
    Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
    Phase
    Phase 2/Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT07185373

    Age 18 years to 75 years (registered criteria)

    Led by Huashan Hospital; 11 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai, Xi'an, Zhengzhou

  172. Recruiting
    Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT07188077

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  173. Recruiting
    PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07188610

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

  174. Recruiting
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07189065

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou

  175. Recruiting
    A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA)
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07191431

    Age 14 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  176. Recruiting
    Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT07198230

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  177. Recruiting
    AI-assisted Diagnosis of Malignant Brain Tumors
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07198256

    Age 18 years to 100 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou

  178. Recruiting
    Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07199296

    Age 14 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  179. Recruiting
    An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07200375

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou

  180. Recruiting
    A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
    Phase
    Early phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07205315

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  181. Recruiting
    Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07208981

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  182. Recruiting
    Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07233720

    Age not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  183. Recruiting
    The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07240194

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  184. Recruiting
    Universal CAR-T Cell Therapy for NHL
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT07248163

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalShanghai

  185. Recruiting
    Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07253129

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  186. Recruiting
    Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07255963

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  187. Recruiting
    Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
    Phase
    N/A
    Started
    2025-08
    Posted
    Registry
    NCT07257510

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  188. Recruiting
    Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07259070

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  189. Recruiting
    KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07260812

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  190. Recruiting
    Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07261163

    Age 18 years to 80 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  191. Recruiting
    Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
    Phase
    Phase 4
    Started
    2025-11
    Posted
    Registry
    NCT07270835

    Age 14 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  192. Recruiting
    Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study
    Phase
    Not given
    Started
    2025-11
    Posted
    Registry
    NCT07270861

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  193. Recruiting
    Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07272499

    Age 14 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  194. Recruiting
    A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07283796

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  195. Recruiting
    Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07284927

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

  196. Recruiting
    Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07299149

    Age 18 years to 90 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  197. Recruiting
    Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT07305337

    Age 18 years to 90 years (registered criteria)

    Led by Zhongnan Hospital of Wuhan UniversityWuhan

  198. Recruiting
    Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07321301

    Age 14 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  199. Recruiting
    A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07350850

    Age 18 years to Not stated (registered criteria)

    Led by Tongji Hospital; 2 listed hospitals as study sitesChangchun, Fuzhou, Wuhan

  200. Recruiting
    Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
    Phase
    Phase 4
    Started
    2025-11
    Posted
    Registry
    NCT07355699

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tongren Hospital; 2 listed hospitals as study sitesBeijing, Shenyang

  201. Recruiting
    Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07371923

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  202. Recruiting
    Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07372365

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  203. Recruiting
    A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Early phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07376642

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Hangzhou

  204. Recruiting
    Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT07448324

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  205. Recruiting
    EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07450391

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  206. Recruiting
    Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07460362

    Age 18 years to 80 years (registered criteria)

    Led by Peking University Third HospitalBeijing

  207. Recruiting
    T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR
    Phase
    Not given
    Started
    2025-10
    Posted
    Registry
    NCT07470996

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  208. Recruiting
    Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07489989

    Age 18 years to 85 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  209. Recruiting
    Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT07508605

    Age 18 years to 75 years (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  210. Recruiting
    Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07754890

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  211. Recruiting
    Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
    Phase
    Not given
    Started
    2025-08
    Posted
    Registry
    NCT07763054

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Central South UniversityHaikou

  212. Recruiting
    Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)
    Phase
    Phase 4
    Started
    2025-10
    Posted
    Registry
    NCT07934537

    Age 18 years to 70 years (registered criteria)

    Led by Tongji HospitalShanghai

  213. Recruiting
    Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
    Phase
    Phase 1
    Started
    2024-03
    Posted
    Registry
    NCT06060782

    Age 18 years to 65 years (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  214. Recruiting
    SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
    Phase
    Phase 3
    Started
    2024-02
    Posted
    Registry
    NCT06122389

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  215. Recruiting
    Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06176027

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  216. Recruiting
    TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06206174

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  217. Recruiting
    A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
    Phase
    Phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06219356

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou

  218. Recruiting
    Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06228963

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  219. Recruiting
    GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06244368

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  220. Recruiting
    The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2024-03
    Posted
    Registry
    NCT06307600

    Age 3 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of USTC; 1 listed hospital as study siteHefei, Wuhan

  221. Recruiting
    A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2024-03
    Posted
    Registry
    NCT06313957

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing, Zhengzhou

  222. Recruiting
    Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06314334

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Shanghai

  223. Recruiting
    Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06321289

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  224. Recruiting
    TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06323525

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  225. Recruiting
    Intratumoral CAN2109 in Subjects With Solid Tumors
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06332430

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  226. Recruiting
    A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06341556

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  227. Recruiting
    CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
    Phase
    Early phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06346912

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  228. Recruiting
    CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
    Phase
    N/A
    Started
    2024-02
    Posted
    Registry
    NCT06355739

    Age 3 years to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  229. Recruiting
    A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06363994

    Age 60 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  230. Recruiting
    CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06365671

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  231. Recruiting
    A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06375733

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanning, Zhengzhou

  232. Recruiting
    Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06376721

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  233. Recruiting
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06378138

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi

  234. Recruiting
    Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06387121

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  235. Recruiting
    Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06393361

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  236. Recruiting
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06395870

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteHefei, Tianjin

  237. Recruiting
    Linperlisib Combined With Chidamide in Patients With PTCL
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06421948

    Age 18 years to 80 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  238. Recruiting
    A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06436677

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing

  239. Recruiting
    Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06445517

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Tianjin

  240. Recruiting
    CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06445803

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanchang, Shanghai

  241. Recruiting
    A Cohort Study in Newly Diagnosed MZL
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06449885

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  242. Recruiting
    Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06454968

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  243. Recruiting
    Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
    Phase
    Phase 1
    Started
    2024-06
    Posted
    Registry
    NCT06464861

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  244. Recruiting
    Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06471738

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  245. Recruiting
    Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
    Phase
    N/A
    Started
    2024-06
    Posted
    Registry
    NCT06478472

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  246. Recruiting
    CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06479356

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  247. Recruiting
    Glofitamab in Chinese Patients With R/R DLBCL
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06481826

    Age 18 years to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  248. Recruiting
    Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06484985

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai

  249. Recruiting
    CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06486337

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  250. Recruiting
    Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06489808

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  251. Recruiting
    A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06494371

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  252. Recruiting
    Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06496308

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  253. Recruiting
    Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06503263

    Age 14 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  254. Recruiting
    Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06504940

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  255. Recruiting
    An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06517004

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  256. Recruiting
    Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06517511

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Shanghai

  257. Recruiting
    Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06519526

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  258. Recruiting
    Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06520163

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated People's Hospital of Ningbo University; 3 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou

  259. Recruiting
    Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06521255

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou

  260. Recruiting
    The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06522555

    Age 70 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  261. Recruiting
    PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06530550

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  262. Recruiting
    Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06534463

    Age 14 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  263. Recruiting
    Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06534762

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Provincial People's HospitalHangzhou

  264. Recruiting
    DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06539182

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  265. Recruiting
    Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06541327

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  266. Recruiting
    Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06553352

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  267. Recruiting
    A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06554561

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  268. Recruiting
    A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06554600

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  269. Recruiting
    A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06556199

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  270. Recruiting
    Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
    Phase
    Phase 2/Phase 3
    Started
    2024-09
    Posted
    Registry
    NCT06563245

    Age 2 years to 35 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  271. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06566586

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  272. Recruiting
    Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06566807

    Age 18 years to Not stated (registered criteria)

    Led by Huai'an First People's HospitalHuai'an

  273. Recruiting
    A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06569485

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  274. Recruiting
    Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
    Phase
    Phase 1/Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06592170

    Age 18 years to Not stated (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  275. Recruiting
    R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06594640

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  276. Recruiting
    BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06598722

    Age 18 years to 60 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  277. Recruiting
    Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
    Phase
    Phase 4
    Started
    2024-09
    Posted
    Registry
    NCT06609304

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  278. Recruiting
    A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06615193

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Suzhou, Tianjin, Xuzhou, Zhengzhou

  279. Recruiting
    Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
    Phase
    Early phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06633341

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  280. Recruiting
    A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06634589

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFuzhou, Hangzhou, Suzhou, Wenzhou

  281. Recruiting
    Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06647940

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Lanzhou, Shantou, Zhuhai

  282. Recruiting
    Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06651853

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  283. Recruiting
    Pola-ZR2P in Previously Untreated DLBCL
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06664411

    Age 14 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  284. Recruiting
    RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06674096

    Age 65 years to Not stated (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  285. Recruiting
    Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06682130

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  286. Recruiting
    A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06683885

    Age 65 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  287. Recruiting
    Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06686108

    Age 14 years to 55 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  288. Recruiting
    CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06696846

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  289. Recruiting
    Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06700798

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Nanchang UniversityNanchang

  290. Recruiting
    Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06704555

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  291. Recruiting
    Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06707259

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  292. Recruiting
    Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research
    Phase
    Early phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06716164

    Age 19 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  293. Recruiting
    JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06716658

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  294. Recruiting
    RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
    Phase
    Phase 1
    Started
    2024-10
    Posted
    Registry
    NCT06732492

    Age 3 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  295. Recruiting
    Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06733051

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteBeijing, Guangzhou

  296. Recruiting
    A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06734871

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  297. Recruiting
    CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06735495

    Age 3 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  298. Recruiting
    Golidocitinib Plus CHOP in Newly Diagnosed PTCL
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06739265

    Age 18 years to 70 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  299. Recruiting
    VHAG in Treating R/R T-ALL/LBL
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06742463

    Age 14 years to 74 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  300. Recruiting
    Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06742502

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteFuzhou

  301. Recruiting
    PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
    Phase
    Not given
    Started
    2024-07
    Posted
    Registry
    NCT06755775

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  302. Recruiting
    Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06824883

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  303. Recruiting
    Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06848569

    Age 1 year to 18 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  304. Recruiting
    CD70-targeted immunoPET Imaging of Malignant Cancers
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06852638

    Age 18 years to 80 years (registered criteria)

    Led by Renji HospitalShanghai

  305. Recruiting
    Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06880913

    Age 12 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  306. Recruiting
    Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06891157

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  307. Recruiting
    The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06911710

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  308. Recruiting
    A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
    Phase
    Phase 1/Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06971523

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  309. Recruiting
    ZR-MTX for PIOL Phase II Trial
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06973811

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  310. Recruiting
    Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT07059741

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  311. Recruiting
    Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT07072208

    Age 70 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  312. Recruiting
    Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT07072221

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  313. Recruiting
    Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT07074457

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  314. Recruiting
    Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT07155954

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  315. Recruiting
    Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT07195799

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  316. Recruiting
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT07234162

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  317. Recruiting
    Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
    Phase
    Not given
    Started
    2024-02
    Posted
    Registry
    NCT07236203

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  318. Recruiting
    Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT07584889

    Age 18 years to 75 years (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  319. Recruiting
    Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma
    Phase
    N/A
    Started
    2024-07
    Posted
    Registry
    NCT07657494

    Age 18 years to Not stated (registered criteria)

    Led by Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing

  320. Recruiting
    Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
    Phase
    Phase 1
    Started
    2023-07
    Posted
    Registry
    NCT05631886

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  321. Recruiting
    Genotype-guided Treatment in Newly Diagnosed PTCL
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT05675813

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  322. Recruiting
    Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
    Phase
    Phase 3
    Started
    2023-02
    Posted
    Registry
    NCT05681260

    Age 12 months to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Shanghai

  323. Recruiting
    Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
    Phase
    Phase 1/Phase 2
    Started
    2023-08
    Posted
    Registry
    NCT05698147

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Hefei, Shanghai, Zhengzhou

  324. Recruiting
    The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2023-04
    Posted
    Registry
    NCT05741359

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Wuhan

  325. Recruiting
    Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05768529

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Shanghai, Suzhou

  326. Recruiting
    A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT05800977

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou

  327. Recruiting
    A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
    Phase
    Phase 1/Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05806099

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  328. Recruiting
    Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
    Phase
    Phase 4
    Started
    2023-05
    Posted
    Registry
    NCT05806580

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  329. Recruiting
    Frontline of ASCT in High-risk DLBCL
    Phase
    Not given
    Started
    2023-05
    Posted
    Registry
    NCT05831865

    Age 18 years to 70 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  330. Recruiting
    Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
    Phase
    Phase 2
    Started
    2023-05
    Posted
    Registry
    NCT05833893

    Age 14 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  331. Recruiting
    Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-01
    Posted
    Registry
    NCT05842707

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  332. Recruiting
    A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
    Phase
    Phase 1
    Started
    2023-10
    Posted
    Registry
    NCT05892718

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  333. Recruiting
    A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
    Phase
    Not given
    Started
    2023-06
    Posted
    Registry
    NCT05899621

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  334. Recruiting
    A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05931263

    Age 18 years to 65 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  335. Recruiting
    A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05933967

    Age 18 years to 70 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  336. Recruiting
    CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT05948033

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  337. Recruiting
    Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT05949931

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  338. Recruiting
    Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05958719

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  339. Recruiting
    Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
    Phase
    Phase 2
    Started
    2023-05
    Posted
    Registry
    NCT05976997

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  340. Recruiting
    TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
    Phase
    Phase 1/Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06014073

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  341. Recruiting
    Real-World Study of DLBCL With Different Genetic Subtypes
    Phase
    Not given
    Started
    2023-10
    Posted
    Registry
    NCT06026488

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  342. Recruiting
    Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
    Phase
    Phase 1
    Started
    2023-09
    Posted
    Registry
    NCT06047197

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  343. Recruiting
    A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06066203

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  344. Recruiting
    PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
    Phase
    N/A
    Started
    2023-12
    Posted
    Registry
    NCT06069830

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  345. Recruiting
    Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06082102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou

  346. Recruiting
    A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT06084936

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou

  347. Recruiting
    A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06090539

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Nanchang

  348. Recruiting
    Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
    Phase
    Early phase 1
    Started
    2023-11
    Posted
    Registry
    NCT06120166

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  349. Recruiting
    Clinical Study of OR for Second-line Treatment of Refractory MZL
    Phase
    Phase 4
    Started
    2023-01
    Posted
    Registry
    NCT06134284

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Ningbo

  350. Recruiting
    A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06136351

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  351. Recruiting
    CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
    Phase
    Phase 1
    Started
    2023-08
    Posted
    Registry
    NCT06136364

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  352. Recruiting
    A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06136559

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou

  353. Recruiting
    Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06151080

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  354. Recruiting
    Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06151106

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  355. Recruiting
    Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06158386

    Age 18 years to Not stated; women only (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  356. Recruiting
    AZA Combined With RCHOP in P53-mutated DLBCL.
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06158399

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  357. Recruiting
    A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06170489

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  358. Recruiting
    Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06176729

    Age 70 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  359. Recruiting
    Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
    Phase
    Phase 1
    Started
    2023-12
    Posted
    Registry
    NCT06180174

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  360. Recruiting
    Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06190067

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  361. Recruiting
    RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
    Phase
    N/A
    Started
    2023-12
    Posted
    Registry
    NCT06190301

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Ophthalmic CenterGuangzhou

  362. Recruiting
    The Pathogenesis and Prognostic Factors of Lymphoma
    Phase
    Not given
    Started
    2023-06
    Posted
    Registry
    NCT06203652

    Age not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  363. Recruiting
    The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06503276

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Ninth People's HospitalShanghai

  364. Recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
    Phase
    N/A
    Started
    2023-09
    Posted
    Registry
    NCT06678282

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  365. Recruiting
    An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
    Phase
    Early phase 1
    Started
    2023-12
    Posted
    Registry
    NCT06693973

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  366. Recruiting
    A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
    Phase
    Early phase 1
    Started
    2023-09
    Posted
    Registry
    NCT06756321

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Nantong UniversityNantong

  367. Recruiting
    A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
    Phase
    N/A
    Started
    2023-12
    Posted
    Registry
    NCT06783816

    Age not stated (registered criteria)

    Led by Shanxi Bethune HospitalTaiyuan

  368. Recruiting
    Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06876688

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou

  369. Recruiting
    Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT07097207

    Age 18 years to 75 years (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  370. Recruiting
    High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
    Phase
    Not given
    Started
    2023-09
    Posted
    Registry
    NCT07205523

    Age not stated (registered criteria)

    Led by Affiliated Hospital of Qinghai UniversityXining

  371. Recruiting
    Cell Free DNA in Mature B-cell Lymphoma
    Phase
    Not given
    Started
    2022-09
    Posted
    Registry
    NCT04088422

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  372. Recruiting
    A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
    Phase
    Phase 1
    Started
    2022-03
    Posted
    Registry
    NCT05091424

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Nanchang, Tianjin

  373. Recruiting
    A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
    Phase
    Phase 2/Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05139017

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou

  374. Recruiting
    A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Phase
    Phase 3
    Started
    2022-07
    Posted
    Registry
    NCT05254743

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan

  375. Recruiting
    R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
    Phase
    Phase 2
    Started
    2022-02
    Posted
    Registry
    NCT05257018

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteUrumqi

  376. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  377. Recruiting
    Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
    Phase
    Phase 1/Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05294731

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  378. Recruiting
    A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
    Phase
    Phase 1
    Started
    2022-08
    Posted
    Registry
    NCT05341557

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesTianjin

  379. Recruiting
    Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
    Phase
    Phase 1
    Started
    2022-07
    Posted
    Registry
    NCT05472558

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  380. Recruiting
    A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
    Phase
    Phase 1/Phase 2
    Started
    2022-07
    Posted
    Registry
    NCT05487170

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  381. Recruiting
    A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
    Phase
    Not given
    Started
    2022-05
    Posted
    Registry
    NCT05498064

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  382. Recruiting
    A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
    Phase
    Not given
    Started
    2022-08
    Posted
    Registry
    NCT05506410

    Age 18 years to 90 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  383. Recruiting
    A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
    Phase
    N/A
    Started
    2022-09
    Posted
    Registry
    NCT05514327

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  384. Recruiting
    TreAtments and outComes in paTients With prImary CutAneous Lymphoma
    Phase
    Not given
    Started
    2022-08
    Posted
    Registry
    NCT05518851

    Age not stated (registered criteria)

    Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing, Jinan

  385. Recruiting
    A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
    Phase
    Phase 1
    Started
    2022-05
    Posted
    Registry
    NCT05528055

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan

  386. Recruiting
    A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Posted
    Registry
    NCT05533775

    Age 6 months to 30 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Nanning

  387. Recruiting
    Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05554939

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  388. Recruiting
    Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
    Phase
    Phase 2
    Started
    2022-08
    Posted
    Registry
    NCT05600660

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  389. Recruiting
    The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
    Phase
    N/A
    Started
    2022-09
    Posted
    Registry
    NCT05618041

    Age 14 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTaiyuan

  390. Recruiting
    CD7 CAR-T Cells in T-cell Lymphoma/Leukemia
    Phase
    N/A
    Started
    2022-10
    Posted
    Registry
    NCT05620680

    Age 18 years to 75 years (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  391. Recruiting
    A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05623982

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Qingdao

  392. Recruiting
    Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
    Phase
    N/A
    Started
    2022-08
    Posted
    Registry
    NCT05626400

    Age 2 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteLangfang

  393. Recruiting
    CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
    Phase
    Phase 1
    Started
    2022-12
    Posted
    Registry
    NCT05659628

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Ningbo

  394. Recruiting
    Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2022-08
    Posted
    Registry
    NCT05660473

    Age 14 years to 60 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  395. Recruiting
    Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
    Phase
    Phase 2
    Started
    2022-11
    Posted
    Registry
    NCT05846750

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  396. Recruiting
    Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
    Phase
    Not given
    Started
    2022-11
    Posted
    Registry
    NCT05846763

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  397. Recruiting
    ZR2 Sequential Immunochemotherapy for Newly Treated MCL
    Phase
    Phase 2
    Started
    2022-08
    Posted
    Registry
    NCT05992597

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  398. Recruiting
    Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
    Phase
    Phase 2
    Started
    2022-11
    Posted
    Registry
    NCT06005870

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  399. Recruiting
    CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2022-01
    Posted
    Registry
    NCT06081478

    Age 14 years to 85 years (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  400. Recruiting
    Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2022-07
    Posted
    Registry
    NCT06909877

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  401. Recruiting
    Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma
    Phase
    N/A
    Started
    2022-12
    Posted
    Registry
    NCT06946407

    Age Not stated to 60 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  402. Recruiting
    High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma
    Phase
    Phase 2
    Started
    2022-01
    Posted
    Registry
    NCT07014943

    Age 16 years to 70 years (registered criteria)

    Led by West China HospitalChengdu

  403. Recruiting
    CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
    Phase
    Early phase 1
    Started
    2021-11
    Posted
    Registry
    NCT04662294

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  404. Recruiting
    Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
    Phase
    Phase 2
    Started
    2021-04
    Posted
    Registry
    NCT04728893

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  405. Recruiting
    Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma
    Phase
    Phase 2
    Started
    2021-01
    Posted
    Registry
    NCT04737889

    Age 18 years to 70 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  406. Recruiting
    Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2021-04
    Posted
    Registry
    NCT04922567

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  407. Recruiting
    Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
    Phase
    Phase 2
    Started
    2021-07
    Posted
    Registry
    NCT04961515

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  408. Recruiting
    Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
    Phase
    Phase 2
    Started
    2021-08
    Posted
    Registry
    NCT04989621

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou

  409. Recruiting
    A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
    Phase
    Phase 1
    Started
    2021-07
    Posted
    Registry
    NCT04993690

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou

  410. Recruiting
    First in Human, Dose Escalation Study of AN4005
    Phase
    Phase 1
    Started
    2021-09
    Posted
    Registry
    NCT04999384

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Harbin, Wuhan

  411. Recruiting
    A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT05006716

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou

  412. Recruiting
    The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
    Phase
    Phase 3
    Started
    2021-09
    Posted
    Registry
    NCT05018520

    Age 14 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  413. Recruiting
    R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden
    Phase
    N/A
    Started
    2021-08
    Posted
    Registry
    NCT05040555

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  414. Recruiting
    Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
    Phase
    Phase 2
    Started
    2021-12
    Posted
    Registry
    NCT05147467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesGuangzhou, Haikou, Hangzhou, Nanchang, Suzhou, Wuhan, Zhengzhou

  415. Recruiting
    Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
    Phase
    Phase 2
    Started
    2021-12
    Posted
    Registry
    NCT05209620

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  416. Recruiting
    Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT06021678

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesJinan, Tianjin, Zhengzhou

  417. Recruiting
    A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
    Phase
    Phase 1
    Started
    2021-03
    Posted
    Registry
    NCT06189391

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou

  418. Recruiting
    A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2021-10
    Posted
    Registry
    NCT06725524

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  419. Recruiting
    Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    Phase
    Phase 2
    Started
    2020-01
    Posted
    Registry
    NCT03936153

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Lanzhou, Linyi, Shanghai, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou

  420. Recruiting
    A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
    Phase
    Early phase 1
    Started
    2020-01
    Posted
    Registry
    NCT04227015

    Age 3 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  421. Recruiting
    A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)
    Phase
    Phase 3
    Started
    2020-05
    Posted
    Registry
    NCT04365036

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  422. Recruiting
    Evaluate the Safety and Clinical Activity of HH2853
    Phase
    Phase 1/Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04390737

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou

  423. Recruiting
    Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
    Phase
    Phase 1/Phase 2
    Started
    2020-06
    Posted
    Registry
    NCT04440436

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  424. Recruiting
    Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
    Phase
    Phase 1/Phase 2
    Started
    2020-08
    Posted
    Registry
    NCT04494503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan

  425. Recruiting
    Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
    Phase
    Early phase 1
    Started
    2020-08
    Posted
    Registry
    NCT04504526

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  426. Recruiting
    Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 2
    Started
    2020-10
    Posted
    Registry
    NCT04586478

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou

  427. Recruiting
    National Longitudinal Cohort of Hematological Diseases
    Phase
    Not given
    Started
    2020-12
    Posted
    Registry
    NCT04645199

    Age not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  428. Recruiting
    CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2020-12
    Posted
    Registry
    NCT04661020

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  429. Recruiting
    Phase Ib Clinical Study of Keynatinib
    Phase
    Phase 1
    Started
    2020-09
    Posted
    Registry
    NCT04807881

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Chengdu, Shanghai

  430. Recruiting
    Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
    Phase
    Phase 2
    Started
    2020-01
    Posted
    Registry
    NCT05182957

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  431. Recruiting
    International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
    Phase
    Phase 3
    Started
    2019-08
    Posted
    Registry
    NCT04043494

    Age Not stated to 18 years (registered criteria)

    Led by University HospitalChangsha

  432. Recruiting
    BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
    Phase
    Phase 1
    Started
    2019-07
    Posted
    Registry
    NCT04162353

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  433. Recruiting
    Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
    Phase
    Not given
    Started
    2019-01
    Posted
    Registry
    NCT04263935

    Age not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  434. Recruiting
    A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
    Phase
    Phase 1
    Started
    2018-04
    Posted
    Registry
    NCT03460977

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Nanjing, Wenzhou

  435. Recruiting
    A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL
    Phase
    Not given
    Started
    2018-03
    Posted
    Registry
    NCT03494296

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Harbin Medical UniversityHarbin

  436. Recruiting
    China Lymphoma Patient Registry Study
    Phase
    Not given
    Started
    2017-05
    Posted
    Registry
    NCT03313271

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  437. Recruiting
    ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
    Phase
    Not given
    Started
    2016-10
    Posted
    Registry
    NCT02848274

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  438. Recruiting
    CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
    Phase
    Phase 1/Phase 2
    Started
    2014-10
    Posted
    Registry
    NCT02259556

    Age 16 years to 80 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  439. Recruiting
    Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
    Phase
    Not given
    Started
    2013-06
    Posted
    Registry
    NCT06795113

    Age 18 years to 100 years (registered criteria)

    Led by Ruijin HospitalShanghai

  440. Recruiting
    Establishing Prospective Mediastinal Tumor Database of PUMCH
    Phase
    Not given
    Started
    2012-01
    Posted
    Registry
    NCT06421805

    Age not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  441. Recruiting
    Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
    Phase
    Phase 2/Phase 3
    Started
    2010-09
    Posted
    Registry
    NCT02657785

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  442. Recruiting
    Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
    Phase
    Phase 2/Phase 3
    Started
    2010-09
    Posted
    Registry
    NCT02836158

    Age 60 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  443. Not yet recruiting
    A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
    Phase
    Phase 1
    Started
    2026-08
    Posted
    Registry
    NCT06970496

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Nanchang, Shanghai, Wenzhou, Xi'an

  444. Not yet recruiting
    CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
    Phase
    Early phase 1
    Started
    2026-04
    Posted
    Registry
    NCT06986434

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  445. Not yet recruiting
    Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07231250

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  446. Not yet recruiting
    Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07334574

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  447. Not yet recruiting
    SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07347288

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  448. Not yet recruiting
    IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07355283

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  449. Not yet recruiting
    Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07367685

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Fujian Medical UniversityQuanzhou

  450. Not yet recruiting
    Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07398638

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  451. Not yet recruiting
    Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07405255

    Age 18 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  452. Not yet recruiting
    Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07459608

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  453. Not yet recruiting
    Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07472621

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  454. Not yet recruiting
    HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
    Phase
    Not given
    Started
    2026-03
    Posted
    Registry
    NCT07483749

    Age 1 year to 21 years (registered criteria)

    Led by Children's Hospital, Zhejiang University School of MedicineHangzhou

  455. Not yet recruiting
    A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07511114

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  456. Not yet recruiting
    U96-CAR-T-Cells For R/R B-ALL
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07511426

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  457. Not yet recruiting
    A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07525817

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  458. Not yet recruiting
    Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07535710

    Age 60 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  459. Not yet recruiting
    Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07535762

    Age 65 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  460. Not yet recruiting
    Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07539610

    Age 18 years to 69 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  461. Not yet recruiting
    Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
    Phase
    N/A
    Started
    2026-06
    Posted
    Registry
    NCT07542912

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  462. Not yet recruiting
    The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07548255

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  463. Not yet recruiting
    Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07554482

    Age 18 years to 75 years (registered criteria)

    Led by Beijing Tongren HospitalBeijing

  464. Not yet recruiting
    A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07574528

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  465. Not yet recruiting
    A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07583771

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  466. Not yet recruiting
    A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07585747

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesJinan, Nanchang, Shenzhen, Tianjin, Zhengzhou

  467. Not yet recruiting
    AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07594899

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  468. Not yet recruiting
    A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07599423

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  469. Not yet recruiting
    Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07601607

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  470. Not yet recruiting
    LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07602322

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  471. Not yet recruiting
    AI-Assisted Optimization of Online Adaptive Radiotherapy for Gastric Lymphoma
    Phase
    N/A
    Started
    2026-05
    Posted
    Registry
    NCT07609355

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  472. Not yet recruiting
    Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07609446

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  473. Not yet recruiting
    Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07613788

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  474. Not yet recruiting
    Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07615283

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  475. Not yet recruiting
    Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07622784

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  476. Not yet recruiting
    Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07638787

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  477. Not yet recruiting
    TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07639879

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  478. Not yet recruiting
    Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07654465

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  479. Not yet recruiting
    A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07658352

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  480. Not yet recruiting
    Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Phase
    Not given
    Started
    2026-06
    Posted
    Registry
    NCT07669194

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  481. Not yet recruiting
    GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07670260

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  482. Not yet recruiting
    A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07676175

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Xi'an

  483. Not yet recruiting
    Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07677813

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun

  484. Not yet recruiting
    Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07684950

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  485. Not yet recruiting
    Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
    Phase
    Not given
    Started
    2026-07
    Posted
    Registry
    NCT07695896

    Age 18 years to Not stated (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  486. Not yet recruiting
    A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07705308

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 2 listed hospitals as study sitesShanghai

  487. Not yet recruiting
    New Genotype-guided Treatment in Newly Diagnosed PTCL
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07706959

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  488. Not yet recruiting
    Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
    Phase
    Phase 2/Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07712588

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Chongqing, Harbin, Shanghai

  489. Not yet recruiting
    AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07717177

    Age 70 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  490. Not yet recruiting
    Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07717580

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  491. Not yet recruiting
    A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07719855

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  492. Not yet recruiting
    Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07744724

    Age 18 years to 65 years (registered criteria)

    Led by Changzhou No.2 People's Hospital; 1 listed hospital as study siteChangzhou, Nanjing

  493. Not yet recruiting
    Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07744737

    Age 18 years to 80 years (registered criteria)

    Led by Changzhou No.2 People's Hospital; 1 listed hospital as study siteChangzhou, Nanjing

  494. Not yet recruiting
    Pirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07744750

    Age 18 years to Not stated (registered criteria)

    Led by Changzhou No.2 People's Hospital; 1 listed hospital as study siteChangzhou, Nanjing

  495. Not yet recruiting
    The Efficacy of CAPCT in Patients With PTCL
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07746245

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  496. Not yet recruiting
    Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07753642

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  497. Not yet recruiting
    A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07758491

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  498. Not yet recruiting
    R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07764601

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangzhou, Nanjing

  499. Not yet recruiting
    GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07768943

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  500. Not yet recruiting
    Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07774234

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  501. Not yet recruiting
    A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07784101

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  502. Not yet recruiting
    Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07812493

    Age 14 years to 80 years (registered criteria)

    Led by Ruijin HospitalShanghai

  503. Not yet recruiting
    A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07818499

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Suzhou

  504. Not yet recruiting
    SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07819188

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  505. Not yet recruiting
    A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07854639

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  506. Not yet recruiting
    A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07855016

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  507. Not yet recruiting
    Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07888621

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  508. Not yet recruiting
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07896590

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  509. Not yet recruiting
    Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07917624

    Age 18 years to 80 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  510. Not yet recruiting
    Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-12
    Posted
    Registry
    NCT07938619

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  511. Not yet recruiting
    Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure
    Phase
    Phase 2
    Started
    2026-12
    Posted
    Registry
    NCT07944651

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  512. Not yet recruiting
    Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma
    Phase
    Phase 2
    Started
    2026-11
    Posted
    Registry
    NCT07945353

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  513. Not yet recruiting
    High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06646211

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  514. Not yet recruiting
    The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study
    Phase
    Not given
    Started
    2025-01
    Posted
    Registry
    NCT06747299

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  515. Not yet recruiting
    Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06757894

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  516. Not yet recruiting
    AZA Combined with R-GemOx for Elderly DLBCL Patients
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06778902

    Age 60 years to 90 years (registered criteria)

    Led by Daping Hospital, Army Medical UniversityChongqing

  517. Not yet recruiting
    Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06788600

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  518. Not yet recruiting
    Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06845241

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Nanchang, Tianjin, Zhengzhou

  519. Not yet recruiting
    The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
    Phase
    Not given
    Started
    2025-03
    Posted
    Registry
    NCT06863441

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  520. Not yet recruiting
    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma
    Phase
    N/A
    Started
    2025-03
    Posted
    Registry
    NCT06879470

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  521. Not yet recruiting
    A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT06886139

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  522. Not yet recruiting
    Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06890585

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  523. Not yet recruiting
    Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06918015

    Age 18 years to 80 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  524. Not yet recruiting
    Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT06925555

    Age 18 years to 70 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  525. Not yet recruiting
    Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
    Phase
    N/A
    Started
    2025-04
    Posted
    Registry
    NCT06935136

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  526. Not yet recruiting
    Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
    Phase
    Phase 4
    Started
    2025-05
    Posted
    Registry
    NCT06956092

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  527. Not yet recruiting
    Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06961500

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  528. Not yet recruiting
    BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07008053

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 5 listed hospitals as study sitesChangsha, Fuzhou, Jinan, Qingdao, Shijiazhuang, Tianjin

  529. Not yet recruiting
    JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07024147

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  530. Not yet recruiting
    A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07032324

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  531. Not yet recruiting
    Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07032532

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  532. Not yet recruiting
    A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07034508

    Age 18 years to 80 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  533. Not yet recruiting
    A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCL
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07035379

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  534. Not yet recruiting
    A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07068906

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  535. Not yet recruiting
    RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07113496

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  536. Not yet recruiting
    CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07117305

    Age 14 years to 65 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  537. Not yet recruiting
    Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07122609

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  538. Not yet recruiting
    Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07159906

    Age 18 years to 99 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  539. Not yet recruiting
    Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
    Phase
    Early phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07168291

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an

  540. Not yet recruiting
    Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07187960

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou

  541. Not yet recruiting
    Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07206264

    Age 60 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 3 listed hospitals as study sitesFuzhou, Harbin, Jinan, Tianjin

  542. Not yet recruiting
    A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
    Phase
    Phase 1
    Started
    2025-11
    Posted
    Registry
    NCT07234045

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  543. Not yet recruiting
    ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
    Phase
    Phase 4
    Started
    2025-12
    Posted
    Registry
    NCT07264894

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  544. Not yet recruiting
    A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07316907

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Jiangsu UniversityChangzhou

  545. Not yet recruiting
    A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07316920

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated Hospital of Jiangsu UniversityChangzhou

  546. Not yet recruiting
    Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    N/A
    Started
    2025-12
    Posted
    Registry
    NCT07345741

    Age 18 years to 78 years (registered criteria)

    Led by Tongji HospitalWuhan

  547. Not yet recruiting
    A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
    Phase
    Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06255704

    Age 18 years to 70 years (registered criteria)

    Led by Shanxi Cancer HospitalTaiyuan

  548. Not yet recruiting
    The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
    Phase
    Phase 3
    Started
    2024-02
    Posted
    Registry
    NCT06255795

    Age 14 years to 70 years (registered criteria)

    Led by Ruijin HospitalShanghai

  549. Not yet recruiting
    Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
    Phase
    N/A
    Started
    2024-02
    Posted
    Registry
    NCT06289959

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  550. Not yet recruiting
    A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06318884

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Zhengzhou

  551. Not yet recruiting
    Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06324994

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteDalian

  552. Not yet recruiting
    A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06368167

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  553. Not yet recruiting
    Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06549335

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  554. Not yet recruiting
    Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06563778

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  555. Not yet recruiting
    JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
    Phase
    Phase 1
    Started
    2024-09
    Posted
    Registry
    NCT06567080

    Age 18 years to 70 years (registered criteria)

    Led by Renji HospitalShanghai

  556. Not yet recruiting
    CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06567366

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  557. Not yet recruiting
    Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06594432

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  558. Not yet recruiting
    ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06646666

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  559. Not yet recruiting
    CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06647329

    Age 14 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  560. Not yet recruiting
    The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
    Phase
    Not given
    Started
    2024-10
    Posted
    Registry
    NCT06656234

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  561. Not yet recruiting
    Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06671717

    Age 18 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  562. Not yet recruiting
    Clinical Study of Improved BEAM Conditioning Regimen for ASCT in Lymphoma
    Phase
    N/A
    Started
    2023-01
    Posted
    Registry
    NCT05681403

    Age 18 years to 60 years (registered criteria)

    Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an

  563. Not yet recruiting
    Real World Study of Linperlisib for Lymphoma Treatment
    Phase
    Not given
    Started
    2023-05
    Posted
    Registry
    NCT05863871

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 1 listed hospital as study siteShanghai, Tianjin

  564. Not yet recruiting
    Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT05909098

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShiyan

  565. Not yet recruiting
    Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06062641

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  566. Not yet recruiting
    Relmacabtagene Autoleucel in Hematologic Malignancies
    Phase
    Not given
    Started
    2023-12
    Posted
    Registry
    NCT06142188

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  567. Not yet recruiting
    A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma
    Phase
    N/A
    Started
    2022-06
    Posted
    Registry
    NCT05343377

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  568. Enrolling by invitation
    A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
    Phase
    Phase 1
    Started
    2026-08
    Posted
    Registry
    NCT07784309

    Age 3 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  569. Enrolling by invitation
    Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06827782

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  570. Enrolling by invitation
    Real-world Study of Acalabrutinib
    Phase
    Not given
    Started
    2024-07
    Posted
    Registry
    NCT06767891

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  571. Enrolling by invitation
    A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma
    Phase
    Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT07348575

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Nanchang UniversityNanchang

  572. Enrolling by invitation
    Efficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
    Phase
    Not given
    Started
    2024-09
    Posted
    Registry
    NCT07450040

    Age 18 years to 70 years (registered criteria)

    Led by Eye & ENT Hospital of Fudan UniversityShanghai

  573. Enrolling by invitation
    AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
    Phase
    Phase 3
    Started
    2023-01
    Posted
    Registry
    NCT05678933

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Where these numbers come from

Papers

3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 18 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions